Nerve damage marker tied to hATTR-PN symptom severity in new study

Increased levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with more severe neurological symptoms in people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), according to a new study from Brazil.

Results also indicated that tafamidis meglumine, the only hATTR-PN therapy covered by Brazil’s public health system, was associated with lower levels of this nerve damage marker. Pfizer’s tafamidis meglumine is approved in Brazil and several other countries outside the U.S. under the brand name Vyndaqel.